Skip to Main Content
Table 2—

Results of IVGTT and euglycemic clamp studies performed during the early third trimester and 15 months postpartum in women who remained nonpreeclamptic and those who developed preeclampsia at delivery

Antepartum
Postpartum
Non-preeclampticPreeclampsiaPNon-preeclampticPreeclampsiaP
n 121 (80.7%) 29 (19.3%)  70 (78.4%) 19 (21.6%)  
IVGTT       
    SI[min−1 · (μU/ml)−1]104 0.63 ± 0.49 0.64 ± 0.37 0.72 1.49 ± 1.06 1.43 ± 0.92 0.53 
    Glucose effectiveness (min−1 · 1020.019 ± 0.004 0.020 ± 0.004 0.10 0.016 ± 0.004 0.016 ± 0.004 0.78 
    AIRg (μU · ml−1 · min) 923.7 ± 1,098.8 928.3 ± 637.9 0.43 550.9 ± 479.0 502.0 ± 472.2 0.21 
    Disposition index 517.4 ± 584.3 547.3 ± 428.3 0.53 772.5 ± 630.2 705.2 ± 587.8 0.63 
Euglycemic clamp study       
    Basal glucose clamp       
        Plasma glucose (mmol/l) 5.39 ± 0.50 5.42 ± 0.60 0.81 6.19 ± 1.52 6.06 ± 1.16 0.73 
        Plasma insulin (μU/ml) 23.4 ± 9.0 29.6 ± 26.1 0.23 20.8 ± 8.1 21.1 ± 7.8 0.82 
        Plasma FFA (μmol/ml) 435.9 ± 111.7 476.9 ± 143.7 0.13 — —  
        Plasma C-peptide (ng/ml) 2.26 ± 0.50 2.37 ± 0.65 0.30 — —  
        Plasma glucagon (pg/dl) 37.5 ± 12.1 35.6 ± 9.9  — —  
        Glucose production (mmol · min–1 · m20.494 ± 0.72 0.508 ± 0.075 0.38 0.381 ± 0.065 0.382 ± 0.045 0.81 
        Glucose clearance (ml · min–1 · m20.097 ± 0.011 0.096 ± 0.012 0.69 0.068 ± 0.013 0.068 ± 0.11 0.89 
    Steady-state glucose clamp       
        Plasma glucose (mmol/l) 4.81 ± 0.11 4.81 ± 0.13 0.77 4.80 ± 0.14 4.85 ± 0.32 0.80 
        Plasma insulin (μU/ml) 101.6 ± 23.1 107.0 ± 31.0 0.37 89.9 ± 20.9 90.3 ± 18.5 0.82 
        Plasma FFA (μmol/ml) 180.9 ± 70.3 181.1 ± 71.5 0.99 — —  
        Plasma C-peptide (ng/ml) 1.48 ± 0.56 1.52 ± 0.71 0.79 — —  
        Glucose production (mmol · min–1 · m20.161 ± 0.060 0.180 ± 0.090 0.32 0.122 ± 0.067 0.149 ± 0.061 0.29 
        Glucose clearance (ml · min–1 · m20.586 ± 0.137 0.555 ± 0.71 0.64 0.172 ± 0.042 0.171 ± 0.064 0.93 
Antepartum
Postpartum
Non-preeclampticPreeclampsiaPNon-preeclampticPreeclampsiaP
n 121 (80.7%) 29 (19.3%)  70 (78.4%) 19 (21.6%)  
IVGTT       
    SI[min−1 · (μU/ml)−1]104 0.63 ± 0.49 0.64 ± 0.37 0.72 1.49 ± 1.06 1.43 ± 0.92 0.53 
    Glucose effectiveness (min−1 · 1020.019 ± 0.004 0.020 ± 0.004 0.10 0.016 ± 0.004 0.016 ± 0.004 0.78 
    AIRg (μU · ml−1 · min) 923.7 ± 1,098.8 928.3 ± 637.9 0.43 550.9 ± 479.0 502.0 ± 472.2 0.21 
    Disposition index 517.4 ± 584.3 547.3 ± 428.3 0.53 772.5 ± 630.2 705.2 ± 587.8 0.63 
Euglycemic clamp study       
    Basal glucose clamp       
        Plasma glucose (mmol/l) 5.39 ± 0.50 5.42 ± 0.60 0.81 6.19 ± 1.52 6.06 ± 1.16 0.73 
        Plasma insulin (μU/ml) 23.4 ± 9.0 29.6 ± 26.1 0.23 20.8 ± 8.1 21.1 ± 7.8 0.82 
        Plasma FFA (μmol/ml) 435.9 ± 111.7 476.9 ± 143.7 0.13 — —  
        Plasma C-peptide (ng/ml) 2.26 ± 0.50 2.37 ± 0.65 0.30 — —  
        Plasma glucagon (pg/dl) 37.5 ± 12.1 35.6 ± 9.9  — —  
        Glucose production (mmol · min–1 · m20.494 ± 0.72 0.508 ± 0.075 0.38 0.381 ± 0.065 0.382 ± 0.045 0.81 
        Glucose clearance (ml · min–1 · m20.097 ± 0.011 0.096 ± 0.012 0.69 0.068 ± 0.013 0.068 ± 0.11 0.89 
    Steady-state glucose clamp       
        Plasma glucose (mmol/l) 4.81 ± 0.11 4.81 ± 0.13 0.77 4.80 ± 0.14 4.85 ± 0.32 0.80 
        Plasma insulin (μU/ml) 101.6 ± 23.1 107.0 ± 31.0 0.37 89.9 ± 20.9 90.3 ± 18.5 0.82 
        Plasma FFA (μmol/ml) 180.9 ± 70.3 181.1 ± 71.5 0.99 — —  
        Plasma C-peptide (ng/ml) 1.48 ± 0.56 1.52 ± 0.71 0.79 — —  
        Glucose production (mmol · min–1 · m20.161 ± 0.060 0.180 ± 0.090 0.32 0.122 ± 0.067 0.149 ± 0.061 0.29 
        Glucose clearance (ml · min–1 · m20.586 ± 0.137 0.555 ± 0.71 0.64 0.172 ± 0.042 0.171 ± 0.064 0.93 

Data are means ± SD. Antepartum data were obtained in the early third trimester prior to the development of preeclampsia and postpartum data at a mean of 15 months after delivery. Data for the basal clamp were obtained during the last 90 min of a 180-min basal tracer infusion, before insulin infusion; those for the steady-state glucose clamp were obtained during the last 30 min of insulin infusion. Postpartum measures of FFA, C-peptide, and glucagons were not evaluated. There were no significant differences between nonpreeclamptic and preeclampsia metabolic parameters measured in antepartum or postpartum tests.

Close Modal

or Create an Account

Close Modal
Close Modal